Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge?Based Immunoassays for European Clinical Laboratories
Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative
Bio-Techne?Launches Simple?Plex?Ultra-Sensitive?Assays on Ella?Platform to Enable?Femtogram-Level?Detection of Neurological Biomarkers
Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
American Uranium Reports Completed Drilling Strengthens Lo Herma Uranium Resource Upgrade for Upcoming Scoping Study
